



US006620850B2

(12) **United States Patent**
Martynyuk et al.(10) **Patent No.:** **US 6,620,850 B2**
(45) **Date of Patent:** **Sep. 16, 2003**(54) **MATERIALS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS INVOLVING OVERACTIVATION OF GLUTAMATERGIC IONOTROPIC RECEPTORS**(75) Inventors: **Anatoly E. Martynyuk**, Gainesville, FL (US); **Donn Michael Dennis**, Gainesville, FL (US); **Alexander V. Glushakov**, Gainesville, FL (US); **Colin Sumners**, Gainesville, FL (US)(73) Assignee: **University of Florida**, Gainesville, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/957,358**(22) Filed: **Sep. 19, 2001**(65) **Prior Publication Data**

US 2003/0055099 A1 Mar. 20, 2003

(51) **Int. Cl.⁷** **A61K 31/198**(52) **U.S. Cl.** **514/567**; 514/419(58) **Field of Search** 514/561, 567, 514/419(56) **References Cited**

U.S. PATENT DOCUMENTS

4,279,917 A	7/1981	Takami et al.	424/273
4,491,589 A	1/1985	Dell et al.	424/274
4,604,286 A	8/1986	Kawajiri	424/149
5,089,517 A	2/1992	Choi et al.	514/411
5,447,948 A	9/1995	Seibyl et al.	514/393
5,605,818 A	2/1997	Katsumata et al.	435/108
5,670,539 A *	9/1997	Richardson	514/561
5,789,444 A	8/1998	Choi et al.	514/567
6,001,575 A	12/1999	Huganir et al.	435/6
6,013,672 A	1/2000	Ye et al.	514/561
6,084,084 A	7/2000	Stormann et al.	536/23.5
6,362,226 B2	3/2002	Phillips, III et al.	514/568

OTHER PUBLICATIONS

Belardinelli, L. et al. "1,3-Dipropyl-8-[2-(5,6-Epoxy)Norbornyl]Xanthine, a Potent, Specific and Selective A₁ Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT₁MF-2 Cells" *J. Pharmacol. Exp. Ther.*, 1995, 275(3):1167-1176.Choi, D.W. "Excitotoxic Cell Death" *J. Neurobiol.*, 1992, 23(9):1261-1276.Dennis, D.M. et al. "Homologous Desensitization of the A₁-Adenosine Receptor System in the Guinea Pig Atrioventricular Node" *J. Pharmacol. Exp. Ther.*, 1995, 272(3):1024-1035.Kostyuk, P.G. et al. "Effects of intracellular administration of L-tyrosine and L-phenylalanine on voltage-operated calcium conductance in PC12 pheochromocytoma cells" *Brain Res.*, 1991, 550:11-14.

Krystal, J.H. et al. "NMDA Agonists and Antagonist as Probes of Glutamatergic Dysfunction and Pharmacothera-

pies in Neuropsychiatric Disorders" *Harv. Rev. Psychiatry*, Sep.-Oct. 1999, 7(3):125-143.Lipton, S.A. and P.A. Rosenberg "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders" *N. Engl. J. Med.*, 1994, 330(9):613-622.Martynyuk, A.E. et al. "Blocking effect of intraperitoneal injection of phenylalanine on high-threshold calcium currents in rat hippocampal neurons" *Brain Res.*, 1991, 552:228-231.Martynyuk, A.E. et al. "Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes" *Cardiovasc. Res.* 1995, 30:668-675.Martynyuk, A.E. et al. "Hyperkalemia Enhances the Effect of Adenosine on I_{K,ADO} in Rabbit Isolated AV Nodal Myocytes and on AV Nodal Conduction in Guinea Pig Isolated Heart" *Circulation*, 1999, 99:312-318.Morey, T.E. et al. "Structure-Activity Relationships and Electrophysiological Effects of Short-Acting Amiodarone Homologs in Guinea Pig Isolated Heart" *J. Pharmacol. Exp. Ther.*, 2001, 297(1):260-266.Morey, T.E. et al. "Ionic Basis of the Differential Effects of Intravenous Anesthetics on Erythromycin-induced Prolongation of Ventricular Repolarization in the Guinea Pig Heart" *Anesthesiology*, 1997, 87:1172-1181.Seubert, C.N. et al. "Midazolam Selectively Potentiates the A_{2A}-but not A₁-receptor-mediated Effects of Adenosine" *Anesthesiology*, 2000, 92:567-577.Tanaka, H. et al. "The AMPAR subunit GluR2: still front and center-stage" *Brain Res.*, 2000, 886:190-207.Weiss, J.H. and S.L. Sensi "Ca²⁺-Zn²⁺ permeable AMPA or kainite receptors: possible key factors in selective neurodegeneration" *Trends Neurosci.*, 2000, 23(8):365-371.Zima, A. et al. "Antagonism of the Positive Dromotropic Effects of Isopoteranol by Adenosine: Role of Nitric Oxide, cGMP-dependent camp-phosphodiesterase and Protein Kinase G" *J. Mol. Cell. Cardiol.*, 2000, 32:1609-1619.Chiaroni, P. et al. "A multivariate analysis of red blood cell membrane transports and plasma levels of L-Tyrosine and L-Tryptophan in depressed patients before treatment and after clinical improvement" *Neuropsychobiology*, 1990, 23:1-7.Dollins, A.B. et al. "L-Tyrosine ameliorates some effects of lower body negative pressure stress" *Physiology & Behavior*, 1995, 57(2):223-230.Eaton, S.A. et al. "Competitive antagonism at metabotropic glutamate receptors (S)-4-carboxyphenylglycine and (RS)- α -methyl-4-carboxyphenylglycine" *European Journal of Pharmacology-Molecular Pharmacology Section*, 1993, 244:195-197.

(List continued on next page.)

Primary Examiner—Phyllis G. Spivack

(74) Attorney, Agent, or Firm—Saliwanchik, Lloyd & Saliwanchik

(57) **ABSTRACT**

The subject invention pertains to methods for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions as ischemia, stroke, spinal cord injury and traumatic brain injury.

26 Claims, 5 Drawing Sheets